Brief: Enlivex Announces Positive Dsmb Recommendation And Imoh Clearance To Continue Phase I/Ii Trial Of Allocetra In Patients With Advanced Solid Tumors
25/01/2023 13:39
Jan 25 (Reuters) - Enlivex Therapeutics Ltd ENLV.TA :
* ENLIVEX ANNOUNCES POSITIVE DSMB RECOMMENDATION AND IMOH
CLEARANCE TO CONTINUE PHASE I/II TRIAL OF ALLOCETRA IN PATIENTS
WITH ADVANCED SOLID TUMORS
* ENLIVEX THERAPEUTICS - IMOH ALSO REVIEWED DATA AND
PROVIDED
REGULATORY CLEARANCE TO CONTINUE STUDY AND OPEN STUDY'S
ADDITIONAL COHORTS
Source text for Eikon: ID:nGNX7cLC81
Further company coverage: ENLV.TA
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Enlivex
See all newsBrief: Enlivex Ltd Registers Up To 23,333,333 Ordinary Shares For Resale By Selling Shareholder
Brief: Enlivex Announces Second Regulatory Approval For Phase 2B Trial Of Allocetra In Age-Related Primary Moderate-To-Severe Knee Osteoarthritis
Brief: Enlivex Therapeutics Files For Offering Of Up To $299.6 Mln Of Ordinary Shares
Brief: Enlivex Announces Positive 6-Month Topline Data For Patients with Knee Osteoarthritis
Brief: Enlivex Files Patent for Allocetra Use in Osteoarthritis Treatment